In February, I published the Mazars Review which examined the governance arrangements around the HSE’s Drug Pricing and Reimbursement Process. I fully support the recommendations contained in the Mazars report around improving the process, increasing transparency, providing easier access, and supporting value for money.
An implementation group has been established between my Department and the HSE to consider and progress the various recommendations contained in the Report. The membership of the Group includes representatives of the Drugs Group, the HSE, the NCPE, and the Department of Health. The Working Group has met frequently since its establishment, to consider the involvement of patients, industry, and clinicians, in each stage of the reimbursement process.
Targeted stakeholder consultation commenced on the 31st of May and concluded on the 20th of June. The insights gained from stakeholders will be considered by the Group as it continues its work on progressing the various recommendations of the Review. A report on this will be submitted to the Minister in the coming months. Submissions to the Group were received from:
Alliance of Rare Disease Companies Ireland
AstraZeneca
BioMarin
Cystic Fibrosis Ireland
Fighting Blindness
Irish Cancer Society
Irish Haematological Society
Irish Pharmaceutical Healthcare Association
Irish Platform for Patient Organisations, Science and Industry
Irish Society of Medical Oncologists
Medicines for Ireland
Multiple Sclerosis Ireland
National Cancer Control Programme
Rare Diseases Ireland
Rare Disease Technology Review Committee
